A Study of AK129 in Patients With Advanced Malignant Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

182

Participants

Timeline

Start Date

March 2, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

June 30, 2026

Conditions

Advanced Malignant Tumors(Stage IA-IB)

Interventions

DRUG

AK129 IV infusion

AK129 is administered intravenously according to the frequency and dosage of administration at different stages.

Trial Locations (1)

RECRUITING

Cancer Hospital Chinese Academy of Medical Science, Beijing